Published: 13 December 2017


Prescriber Update Quiz 2017 Answers

This article is more than five years old. Some content may no longer be current.

Prescriber Update 38(4):
December 2017


Have you read your copy of Prescriber Update in 2017?

Have you kept up to date with emerging safety signals?

Test your knowledge with the end of year Prescriber Update quiz.

Answers to the quiz are available at the bottom of page 63 or

  1. True or false: The major safety concern with the use of levetiracetam is an increase in mood disorders, including suicidality, and patients should be monitored for changes in behaviour.
  2. Which of the following statements is false?
    1. If a pharmaceutical company wishes to sell or distribute a medicine in New Zealand, data from pre-clinical studies is not needed.
    2. Before a medicine can be sold in New Zealand, an application must be submitted to Medsafe to seek the Minister's consent to distribute the medicine.
    3. Applications can be made for provisional consent where there is a clinical need for the medicine and use is expected to be in a limited number of patients.
    4. The Medicines Assessment Advisory Committee can provide advice to the Minister of Health in instances where Medsafe is not able to recommend that consent to distribute a medicine in New Zealand is granted.
  3. True or false: It is safe to give Zostavax vaccine to patients who are immunosuppressed or immunodeficient.
  4. What medicine is currently on Medsafe’s scheme associated with a possible effect on blood glucose control when used in patients with type 2 diabetes?
    Viekira Pak, Viekira Pak-RBV
  5. Which of these medicine classes are associated with a high (>10%) risk of hepatitis B reactivation?
    1. TNF-α inhibitors
    2. Tyrosine kinase inhibitors
    3. B-cell depleting agents
    4. Cytokine inhibitors and integrin inhibitors
  6. True or false: Olanzapine has not been associated with DRESS.
  7. Which of the following is not a consequence of JC virus reactivation?
    1. Progressive Multifocal Leukoencephalopathy
    2. Granule Cell Neuronopathy
    3. Guillain Barre Syndrome
    4. Encephalopathy
  8. It is important to regularly monitor which of the following in all patients taking methotrexate.
    1. Renal function
    2. Liver function
    3. Respiratory symptoms
    4. Full blood count
    5. All of the above
  9. True or false: Tramadol is contraindicated in children under two years of age.
  10. Which of the following topical corticosteroids is the most potent?
    1. Hydrocortisone 1%
    2. Betamethasone dipropionate 0.05% in propylene glycol base
    3. Betamethasone dipropionate 0.05%
    4. Clobetasone butyrate 0.05%
Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /